Plain-English translation of NCT06666712 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new way to treat recurrent malignant gliomas—aggressive brain tumors that have returned after initial treatment. Instead of giving chemotherapy through the bloodstream (where it struggles to reach brain tumors effectively), researchers will use a surgically implanted pump system to deliver , a cancer-fighting drug, directly into the tumor. The goal is to see if this direct delivery method is safe and effective for patients with specific types of recurrent brain tumors.
Standard chemotherapy treatments don't work well against recurrent brain tumors because the blood-brain barrier—a natural shield around the brain—prevents most drugs from reaching tumor cells in effective amounts. This trial exists to test whether bypassing that barrier by delivering medicine directly to the tumor site can improve outcomes and safety.
You likely qualify if…
You likely don't qualify if…
If enrolled, you will undergo a surgical procedure to have a small pump implanted under your skin that will continuously deliver the medication directly into your brain tumor over several weeks. You will receive four separate 48-hour infusions of the medication spaced over 23–29 days, with brief breaks between treatments. During the trial, you will have imaging scans to monitor how the medication is being delivered and how your tumor is responding, along with regular clinic visits and blood work to check for side effects.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States